019736 S70 M5 vr tm 10294

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

19

Download PDF ↗ Live URL (may be dead)

Document text

VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 1
TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 2
LIST OF FIGURES ................................ ................................ ................................ ................... 2
1.HISTORICAL REVI SIONSUMMARY ................................ ................................ ..............3
2.PURPOSE ................................ ................................ ................................ .............................. 3
3.SCOPE................................ ................................ ................................ ................................ ...3
4.GLOSSARY ................................ ................................ ................................ .......................... 3
5.GENERAL ................................ ................................ ................................ ............................. 4
6.RESPONSIBILIT IES................................ ................................ ................................ ............4
7.SAFETY ................................ ................................ ................................ ................................ 5
8.MATERIAL S/EQUIPMENT ................................ ................................ ................................ 5
8.1. Equipment................................ ................................ ................................ ................. 5
8.2.Materials ................................ ................................ ................................ .................... 6
8.3.Reagents................................ ................................ ................................ .................... 7
8.3.1.Standard and QCS, Prepared as Described in VR -RGR-RS-10747............. 7
8.3.2.Microspheres ................................ ................................ ................................ .7
8.3.3.Secondary  Antibody ................................ ................................ ..................... 7
8.3.4. ................................ ................................ ................................ ...............7
8.3.5.Buffers................................ ................................ ................................ ..........7
9.PROCEDURE ................................ ................................ ................................ ........................ 8
9.1.Preparation of Single-plex RBD Microspheres ................................ ......................... 9
9.2.Preparation of Sample Dilution Plates ................................ ................................ ......9
9.2.1.RoboticPreparation of Dilution Plates ................................ ......................... 9
9.2.2. Manual Preparation of Dilution Plates................................ ....................... 10
9.2.2.1.Reference Standard ................................ ................................ ...10
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
FDA-CBER-2021-5683-1072957
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 29.2.2.2.Unknown Specimen and QCS................................ ................... 11
9.2.2.3.Samples Requiring Pre -dilutions................................ ...............11
9.2.2.4.Dilution Plate Completion ................................ ......................... 12
9.3.Preparation of Assay Plates ................................ ................................ ..................... 12
9.3.1.Robotic Preparation of Assay  Plates................................ ........................... 12
9.3.2.Manual Preparation of Assay  Plates................................ ........................... 12
9.4.Primary Incubation of RBD Coated Microspheres with Sera ................................ .12
9.5.Preparation of  Plate Washer ................................ ................................ .........13
9.6.  Secondary  Antibody  Preparation and Incubatio n........................... 13
9.7.Assay Completion ................................ ................................ ................................ ...14
9.8.Reading Assay  Plates on the Bio -Plex  I nstrument ................................ ...........14
9.9.Rereading of Assay  Plates Due to Errors ................................ ................................ 15
9.10.Electronic Documentation ................................ ................................ ..................... 15
9.11.Data Export and Primary  Data Review................................ ................................ .16
10.INTERPRETATION OF R ESULTS ................................ ................................ ................. 17
11.REFERENCES ................................ ................................ ................................ .................. 17
12.DOCUMENT VERSION MOD IFICATIONS................................ ................................ ..18
12.1.CRIF Number: VR -CRIF-20-14620................................ ................................ .....18
LIST OF TABLES
Table 1. Chronological Summary  of Previous Versions................................ ..........3
Table2. Vaccine Research Functional Units ................................ ............................ 3
Table3. Terms and Definitions................................ ................................ ................ 3
Table4. Roles and Responsibilities................................ ................................ ..........5
Table 5. General References ................................ ................................ ................... 17
Table 6. Form References ................................ ................................ ....................... 17
Table 7. Specific References ................................ ................................ .................. 17
Table 8. Detailed Changes ................................ ................................ ...................... 18
LIST OF FI GURES
Figure1. Dilution Plate Diagram ................................ ................................ .............10
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072958
FDA-CBER-2021-5683-1072959
FDA-CBER-2021-5683-1072960
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 5Table4.Roles and Responsibilities
Role Responsibilities
Analyst Performs the test method foll owing the procedures described in this SOP.
Completesdocumentation of the w ork perform ed and any deviations that occurred .
Follows applicable depar tmentalSOPs regarding safety , equipment use an d 
documentation practices .
Initiates LDRs .
Notifies superviso r of any at ypical events.
Supervisor or 
designeeReviews and signs documentation. 
Ensuresthat analysts have been trained on appropriate SOPs.
Ensuresthat equipment and instr uments have been p roperly calibrated and maintained.
Ensures LDRs are initiated and proper ly investigated.
7.SAFETY
Biosafety level 2 precautions should be taken when handling human sera. For current 
guidelines refer to the CD C/NIH Biosafety in Microbiolo gical and Biomedic al 
Laboratories Manual (BMBL), 5th Ed., 2009: 
http://www.cdc.gov/biosafe ty/publications/bmb l5/index.htm.
Personnel must be trained on current labora torysafety procedures and made aware of the 
Safety Data Shee ts (SDS) for chemicals being used, before perfo rming this procedure. 
For SDS information, refer to link at http:// .
All laboratory work is to be carried ou t incompliance with Pfizer safet y policies.  For 
general lab oratorysafety guidelines con sult the Pearl Riv er Environmental Health and 
Safety Laboratory  Manual located at: 
http:/ .
Lab coats, safet yglasses and disposable gloves must be worn at all times when handling 
human specimens .
8.MATERIALS/EQUIPMENT
All equipment and materials used in regulated testing must co nform to cu rrent departmental 
guidelines for calib ration, maintenance and qualification.
8.1.Equipment
Bio-Plex Reader, Bio -Rad Cat. #  orequivalent
Platform Shaker,  or equivalent
Scientific freezers, -80°C ±15°C and -20°C -15/+5°C
Scientific ref rigerator,2 to 8°C
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072961
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 6 (magnetic bead) plate washer or equiva lent
Alarm timer
Single channel pipettes, various sizes
Multi-channel pipettes, manual and electronic, vario us sizes
  Pipetting Device,  or equivalent
Vortex m ixer
Nutating mixer
8.2.Materials


96-well flat bottom opaque white plates,  or equivalent
Polypropylene pipette tips, various sizes 
Sterile disposable serological plastic p ipettes, various sizes
Disposable polypropylene tubes or container s, various sizes
Disposable light protective amber pol ypropylene centrifuge tubes or conta iners, various 
sizes
Aluminum sealing tape for 96 well plates
Reagent Reservoir s, various sizes
Polypropylenemicro snap cap tube s
Tube racks
Magnetic separators
Biohazardous waste receptacle
Biohazard sharps waste containers
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072962
FDA-CBER-2021-5683-1072963
FDA-CBER-2021-5683-1072964
FDA-CBER-2021-5683-1072965
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 109.2.2.Manual Preparation of Dilution Plates
4.See Figure1for the Dilution Pla te Diagram.
Figure1. Dilution Plate Diagram
9.2.2.1.Reference Standard 
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072966
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 119.2.2.2.Unknown Specimenand QCS
9.2.2.3.Samples Requ iring Pre- dilutions
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072967
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 129.2.2.4.Dilution Plate Completion
9.3.Preparation of Assay Plates
9.3.1.RoboticPreparat ion of Assay Plates
Referto VR-SOP-LC-11186for assay plate preparation using the  
Robot.  Continue to Section 9.4to begin a ssay completion steps .
9.3.2.Manual P reparation of Assay Plat es
9.4.Primary Incubation of RBDCoated Microspheres with Sera
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072968
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 139.5. Preparation of  PlateWasher
1.Prepare  plate washer for use as described in VR -SOP-FE-10887.  Record the 
activities, as required, in the appropriate equipment logbook .
2.Ensure the Magnetic Bead Plate Adapto r is inserted for mag netic bead plate wash.
9.6.  Secondary Antibody Preparat ion and Incubation
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072969
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 149.7.Assay Completion
9.8.Reading Assay Plat es on the Bio- Plex  Instrument
1.Prepare the Bio-P lex reader for use as described in VR -SOP-FE-10111.  Rec ord the 
activities, as required in the appropri ate equipment logbook.
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072970
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 159.9. Rereading of Assay Plate s Due to Errors
6.Prepare assay  plates for disposal by  emptying the liquid off the plates.  Discard empt
y
assay plates in a Biohazardwaste receptacle .
9.10.Electronic Documentation
VR-TM-10294-FM01 is the assay  completion worksheet used whensample pr eparation 
is performed either manually  or by automated methods.  A n assay completion worksheet 
is not required for fully electronic/paperless batches where metadata is recorded in LIMS.
VR-TM-10294-FM02 is the manual sample preparation workshe et used when a utomated 
sample preparation is not performed .  An assay  completio n worksheet is not required for 
fully electronic /paperless batches where metadata is recorded in L IMS.
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072971
FDA-CBER-2021-5683-1072972
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 1710.INTERPRETA TION OF RES ULTS
A qualified data reviewer anal yzes the data accordi ng to pre-specified acceptance criteria, as 
described in VR-SOP-LC-1112 0.
11.REFERENCES
Table 5.General References
Document Title
VR-SOP-QU-10004 Documen tation Pract ices in Vacci ne Research
VR-GWP-10041 Metadata Entry Procedure in LabWare LIMS for Luminex Immunoassays
VR-SOP-QU-10726 Laboratory Devi ation Report
VR-SOP-LC-10788 Labeling and Traceability of Reagents and Solutions
Table 6.Form References
Form Title
VR-TM-10294-FM01 Assay Complet ion Worksheet for SARS-CoV-2RBDIgG dLIA
VR-TM-10294-FM02Manual Sample Preparation Wo rksheet for SARS-CoV-2 RBDIgGdLIA
VR-SOP-LC-10601-FM14Generic Luminex Assay Data Package Chain ofCustody
Table 7. Speci fic References
Document Title
VR-SOP-LC-10222 Procedure for M aking Sample Predilutions with  
Robot
VR-SOP-LC-10627 Preparation of Assay Buffers and Solutions for  Assays
VR-SOP-LC-11114 DataReview Procedures for Dir ect Luminex I mmunoassays Using Input Files or 
LabWare v5 LIMS
VR-SOP-LC-11120 Data Review Procedures f or Direct Luminex Immunoassays in LIMS v6.
VR-SOP-LC-11186 Running the Method Using  Robot
VR-SOP-LC-11190 Standard Operating Procedure f or Running Predilute Sample Method using 
 Robot
VR-SOP-LC-11295 Preparation of and Evaluation of  Microspheres for use in Direct 
Luminex Assays
VR-RGR-RS-10747 Preparation of Reference Standard Seru m and Quality Control Samples for 
SARS-CoV-2 S1 and RBD Direc t Luminex Immunoass ays
VR-SOP-FE-10111 Bio-PlexSystem Operation and Maintenance
VR-SOP-LC-10586 LiquidHandling Techniques for Regulated Laborato ryProcedures
VR-SOP-LC-10601 Data Package Chain of Custody
VR-SOP-LC-10774 Specimen Ma nagement Record Using LabWare LIMS
VR-SOP-FE-10887 Operation, Main tenance and Per formance Verificati on of  
Microplate Washers
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1072973
VACCINE RESEA RCH TEST METHOD PEARL RIVER, NY 
TITLE:Single-plex Luminex Assay for Qu antitation of 
IgGAntibodies toSARS-CoV-2RBDProteinin Human 
SerumDoc Number: VR-TM-10294 Version: 1.0
Doc. Alias: NA
PFIZER CO NFIDENTIAL
Page 1812.DOCUMENT VERSION MOD IFICATIONS
12.1.CRIF Number: VR-CRIF-20-14620
Table 8. Detailed Changes
List detailed changes for document( s) 
Includesection number(s) for eachList rationale for each chan ge
New NA
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
FDA-CBER-2021-5683-1072974
Document Approval Record
Document Name:	


Document Title:    !"""  #$ "%& " 
' ()  "  *  
Signed By: Date(GMT) Signing Capacity
+, -   ./ 0.01 	  2
./ 0
04 !"  5  2
7/ 
0
40. 8  2
92:2, ): 7/ 
0
40;. 	  2
6, $& 
/ 

04.07 "6  2
Only Valid on 25-Aug-2020 (GMT)\090177e1944c7efd\Effective\Effective On:13-Jul-2020 (GMT)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-1072975